Results of a study examining ibrutinib combined with venetoclax for first line treatment of CLL.
Home / Resource Library / Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities
Results of a study examining ibrutinib combined with venetoclax for first line treatment of CLL.